Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or...
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...
Sanofi (SNY) to Acquire Provention Bio (PRVB) for $25 a Share. Gains 243%.
Up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of hard...
We’re Bearish, but we’re up 243% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of...
Unicycive Therapeutics (UNCY) $2.73 Tacks on Another 30%. We’re now up 249%.
Quick way to Jinx Things...
Stormin..Live Quote
We're still not...
New Player in the Electric Vehicle (EV) Market?
Principal Solar (PSWW) Highlights one of it's Portfolio Holdings, eTruck Transportation.
Alternative Energy...
Unicycive (UNCY) Shoots and Scores, up 40% Today!
We're up 126% Since December, and That Ain't Bad.
Note: This isn't the end, it's just the...
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers. Unicyive...
Los Altos, CA --News Direct-- Unicycive Therapeutics, Inc.
By Julian Richard, Benzinga
Unicycive Therapeutics Inc (NASDAQ: UNCY)...
Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35%...
We Warned About VERU (VERU) $2.50, Down 89%.
Down 35% Today, and 89% from $24, and a $1.9 Billion Market Cap, Only 7 Months ago.
The FDA...